Prime Medicine (PRME) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Prime Medicine (PRME) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.35 of bullish evidence against -0.36 bearish.

Prime Medicine last closed at $3.90, +11.43% on the session.

Against the IVW growth benchmark the position is +11.59% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

16 graded predictions for PRME so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Prime Medicine in the 5th percentile on return on equity, where 100 is best.

Prime Medicine is classified under Health Care / Biotechnology, with a market capitalisation of $634.82M.

StockMap tracks Prime Medicine as the 163rd largest of the 377 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 198 Moderate Underperform, 166 Neutral and 13 Strong Underperform.

On that composite Prime Medicine ranks 254th of 377 in the group, against a group median of -0.21.